 PRINCETON, N.J., June 10, 2021 GLOBE NEWSWIRE -- Oyster Point Pharma, Inc. Nasdaq: OYST, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, today announced a newly formed research collaboration with Adaptive Phage Therapeutics APT to leverage APTs PhageBankTM technology for the development of potential treatments for multiple ophthalmic diseases. 